Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

Vinay Prasad

doi:10.1038/nrclinonc.2017.156

Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

177 Scopus citations

Original language	English (US)
Pages (from-to)	11-12
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/nrclinonc.2017.156
State	Published - Jan 1 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2017.156

Cite this

@article{e9af20e84c2e437aa17c6c03806394ce,

title = "Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers",

author = "Vinay Prasad",

note = "Funding Information: The work of the author is funded by the Laura and John Arnold Foundation. The author also receives royalties from his book Ending Medical Reversal: Improving Outcomes, Saving Lives.",

year = "2018",

month = jan,

day = "1",

doi = "10.1038/nrclinonc.2017.156",

language = "English (US)",

volume = "15",

pages = "11--12",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Tisagenlecleucel - The first approved CAR-T-cell therapy

T2 - Implications for payers and policy makers

AU - Prasad, Vinay

N1 - Funding Information: The work of the author is funded by the Laura and John Arnold Foundation. The author also receives royalties from his book Ending Medical Reversal: Improving Outcomes, Saving Lives.

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85038247975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038247975&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2017.156

DO - 10.1038/nrclinonc.2017.156

M3 - Comment/debate

C2 - 28975930

AN - SCOPUS:85038247975

SN - 1759-4774

VL - 15

SP - 11

EP - 12

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 1

ER -

Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this